Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Therapy for overactive detrusor using propiverine].

S Alloussi1, M Goepel, A E Richter

  • 1Städtisches Klinikum, Urologische Abteilung, Neunkirchen. schahnaz.alloussi@krh-nk.de

Der Urologe. Ausg. A
|March 9, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response to Correspondence to "Short-course subcutaneous treatment with PQ Grass strongly improves symptom and medication scores in grass allergy".

Allergy·2024
Same author

Short-course subcutaneous treatment with PQ Grass strongly improves symptom and medication scores in grass allergy.

Allergy·2023
Same author

[Interventional bronchoscopy-an overview].

Der Pneumologe·2021
Same author

[Recommendations for Performing Bronchoscopy in Times of the COVID-19 Pandemic - Update 12/2020].

Pneumologie (Stuttgart, Germany)·2020
Same author

[Recommendations for Performing Bronchoscopy in Times of the COVID-19 Pandemic].

Pneumologie (Stuttgart, Germany)·2020
Same author

[Joint Statement of the German Respiratory Society and German Society of Thoracic Surgery in Cooperation with the German Radiological Society: Structural Prerequisites of Centers for Interventional Treatment of Emphysema].

Pneumologie (Stuttgart, Germany)·2020
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
See all related articles

Propiverine hydrochloride effectively reduced incontinence episodes and improved bladder voiding in overactive bladder patients. The treatment demonstrated a favorable risk-benefit profile with good tolerability and minimal adverse effects like dry mouth.

Area of Science:

  • Pharmacology
  • Urology
  • Clinical Trials

Background:

  • Overactive bladder (OAB) significantly impacts quality of life.
  • Evaluating real-world efficacy and safety of OAB treatments is crucial.
  • Propiverine hydrochloride is a recognized treatment for OAB symptoms.

Purpose of the Study:

  • To assess the efficacy and tolerability of propiverine hydrochloride in daily practice.
  • To evaluate the risk-benefit relationship of propiverine in a large patient cohort.
  • To analyze treatment outcomes using micturition diary data.

Main Methods:

  • A 12-week, multicenter, post-marketing surveillance study.
  • Involved 2,932 patients diagnosed with overactive bladder symptoms.
  • Micturition diary parameters (incontinence, frequency, volume) were recorded at baseline, 4, and 12 weeks.

Related Experiment Videos

Main Results:

  • Significant reduction in daytime (3.6 to 1.2 episodes) and nighttime (1.5 to 0.4 episodes) incontinence (P<0.001).
  • Mean voiding volume increased by 49.5% (142.7 ml to 213.3 ml; P<0.0001).
  • 85% of investigators rated efficacy as good/very good; 70% reported good/very good tolerability, with dry mouth as the most common side effect (17.3%).

Conclusions:

  • Propiverine hydrochloride demonstrates significant efficacy in reducing incontinence and improving voiding parameters in OAB patients.
  • The drug exhibits a favorable risk-benefit profile with good tolerability and manageable side effects.
  • Real-world data supports the use of propiverine hydrochloride for managing overactive bladder.